Sana Biotechnology (NASDAQ:SANA) Lowered to “Hold” Rating by Zacks Research

Sana Biotechnology (NASDAQ:SANA) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Bank of America lifted their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Wedbush increased their price target on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Finally, HC Wainwright lowered their target price on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sana Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $7.83.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $3.82 on Tuesday. The stock has a fifty day moving average of $4.30 and a two-hundred day moving average of $4.14. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $6.55. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -3.94 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, analysts forecast that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC increased its position in shares of Sana Biotechnology by 189.4% in the 4th quarter. Virtu Financial LLC now owns 119,312 shares of the company’s stock worth $486,000 after purchasing an additional 78,088 shares during the last quarter. Invesco Ltd. grew its stake in Sana Biotechnology by 24.1% in the fourth quarter. Invesco Ltd. now owns 561,835 shares of the company’s stock worth $2,287,000 after purchasing an additional 109,078 shares in the last quarter. XTX Topco Ltd increased its holdings in Sana Biotechnology by 9.9% in the fourth quarter. XTX Topco Ltd now owns 117,376 shares of the company’s stock valued at $478,000 after buying an additional 10,581 shares during the last quarter. VARCOV Co. acquired a new stake in Sana Biotechnology during the fourth quarter valued at approximately $264,000. Finally, Virtus Investment Advisers LLC lifted its holdings in Sana Biotechnology by 15.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 51,756 shares of the company’s stock worth $211,000 after buying an additional 6,958 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.